Brainstorm Cell Therapeutics (NASDAQ:BCLI) Cut to Sell at StockNews.com
StockNews.com lowered shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) from a hold rating to a sell rating in a research note issued to investors on Sunday morning. Brainstorm Cell Therapeutics Stock Performance Shares of NASDAQ BCLI opened at $1.84 on Friday. The firm has a market cap of $67.23 million, a price-to-earnings ratio […]